Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

NCT00984620 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: BI 201335
DRUG: BI 201335
DRUG: Pegylated Interferon-alpha (IFN)
DRUG: Ribavirin (RBV)

Sponsor

Boehringer Ingelheim